What Are Analysts Opinions On Seattle Genetics, Inc. (SGEN)

13 October, 2017, 04:44 | Author: Regina Silva

Since May 5, 2017, it had 0 insider purchases, and 3 selling transactions for $2.20 million activity.

ICON public limited company is a contract research organization, which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. However, dependence on one product - Adcetris- for growth has its inherent risks.The recent label expansion of Merck's Keytruda in the lymphoma indication is likely to increase competition.

Multiple company employees have indulged in significant insider trading. The company had Year Ago Sales of 106.31 Million. Estimates have remained stable ahead of the Q3 earnings results. On Friday, July 14 the stock rating was maintained by Barclays Capital with "Hold". Currently, the 14-day ADX for Seattle Genetics Inc (SGEN) is 43.89. The CCI technical indicator can be used to help determine if a stock is overbought or oversold.

There has been some selling insider activity on Seattle Genetics, Inc.

Some buy side analysts are also providing their Analysis on Seattle Genetics, Inc., where 2 analysts have rated the stock as Strong buy, 4 analysts have given a Buy signal, 9 said it's a HOLD, 1 reported it as Underperform and 0 analysts rated the stock as Sell.

Carragher names his XI of the Premier League season so far
And here is what the Liverpool legend came up with - and he gave his explanation on each selection. Carragher delivered his verdicts to the Daily Telegraph .


Alphabet Inc. (GOOGL) Shares Sold by Eastern Bank
The price target indicates a potential upside of 34.24 % from the last stock close price of Alphabet (NASDAQ: GOOGL ). Return on assets is 11.40% and Return on equity (ROE) is 13.70% while it's Return on Investment (ROI) of 13.30%.


GM Idling Production At Detroit-Hamtramck Assembly Plant
As consumer attitudes shift, automakers don't want to be stuck with a bevy of unwanted passenger cars. GM confirmed the report , saying it intends to keep its current production in line with demand.


Shares of Seattle Genetics Inc (SGEN) have a 200-day moving average of 58.89. The 14 day Williams %R for Seattle Genetics Inc (SGEN) is noted at -16.23. Icon plc had 23 analyst reports since July 29, 2015 according to SRatingsIntel. Moving averages are considered to be lagging indicators that simply take the average price of a stock over a certain period of time. Cognios Capital Llc who had been investing in Altria Group Inc for a number of months, seems to be less bullish one the $124.73 billion market cap company.

The average Wall Street analyst rating for Seattle Genetics, Inc.is Hold, according to the average of 13 analyst scores. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.03. The business had revenue of $108.20 million during the quarter, compared to analysts' expectations of $105.92 million. The return on equity ratio or ROE stands at 2.6 percent while most common profitability ratio return on investment (ROI) was 5.1 percent. During the same period in the previous year, the company posted ($0.23) earnings per share. Next quarter's EPS is forecasted to be $-0.45 and the next full year EPS is anticipated to be $-1.22. Seattle Genetics Inc (SGEN) presently has a 14-day Commodity Channel Index (CCI) of 125.75. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US & worldwide trademark and copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/10/12/seattle-genetics-inc-sgen-stock-rating-upgraded-by-zacks-investment-research.html. The SEC filing shows that Himes Vaughn B performed a sale of 10,000 shares. The shares were sold at an average price of $54.54, for a total transaction of $545,400.00.

According to Seattle Genetics, Inc.'s latest 13F filing with the US Securities and Exchange Commission (SEC), institutional ownership is at 98.83%. Also, EVP Darren S. Cline sold 1,788 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $48.91, for a total transaction of $509,299.83. The disclosure for this sale can be found here. Vaughn B. Himes, CTO sold $530,900 worth of shares at an average price of $53.09 on Friday the 8th. (NASDAQ:SGEN). 20,200 are owned by Tributary Mgmt Ltd Liability Company.

Several large investors have recently made changes to their positions in SGEN. The stock witnessed 15.65% gains, 13.64% gains and -4.4% declines for the 1-month, 3-month and 6-month period, respectively. More interesting news about Seattle Genetics, Inc. Capital International Investors grew its position in Seattle Genetics by 34.3% during the second quarter. Goldman Sachs initiated the shares of SGEN in report on Wednesday, November 18 with "Sell" rating. Beta value of the stock is marked at 2.38. BlackRock Inc. grew its position in Seattle Genetics by 2.6% during the second quarter. More interesting news about Seattle Genetics, Inc. The Virginia-based Akre Capital Management Llc has invested 11.27% in the stock. Institutional investors own 97.63% of the company's stock.

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer.

Recommended:



Popular

Unusual Activity Spotted in Star Gas Partners LP (SGU)
On average, equities research analysts forecast that Star Gas Partners, L.P. will post $0.55 EPS for the current fiscal year. National Bank & Trust Of Montreal Can invested in 0% or 3,725 shares. 2,000 were reported by Evercore Wealth Management.

Debate erupts over resurfaced video of Jason Momoa making a rape joke
The clip of the Justice League actor resurfaced after a number of recent discussions of sexual harassment by men in Hollywood.

Nutanix, Inc. (NTNX) stock RSI 71.88 signaled a sell opportunity
But given these two votes of confidence from Wall Street today, it's no surprise to see Nutanix shares popping right now. PNC Financial Services Group Inc. purchased a new stake in shares of Nutanix in the second quarter valued at $208,000.

General Electric Company 4.875% (NYSE:GEB) Experiences Lighter than Usual Trading Volume
Stifel Nicolaus restated a "buy" rating and issued a $26.00 price target on shares of General Electric in a report on Thursday. The New England Investment & Retirement Group Inc holds 8,384 shares with $374,000 value , down from 28,902 last quarter.

Pokemon UltraSun and UltraMoon trailer unleashes new Z-Moves
Necrozma can absorb the Legendary Pokemon Solgaleo and Lunala, giving its Attack or Special Attack stats a massive boost. For instance, Rotom will eventually be able to influence battle by allowing trainers to use a second Z-Move.

Star Wars Battlefront 2: Most Powerful Items Will Be Earned In-Game
We're assured that "the complete system was not in the beta and [it] will continue to be tuned over time". However, I keep seeing people say "well, just don't buy the loot boxes".

Ireland's 1st Test vs Pak in May
The date and venue for the encounter will be announced by the Ireland board in due course of time. Ireland will play Pakistan at home in May in their first cricket test.

CAPROCK Group Inc. Sells 1933 Shares of Walt Disney Company (The) (DIS)
The entertainment giant reported $1.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.45 by $0.05. Bernstein reaffirmed a "market perform" rating on shares of Walt Disney Company (The) in a report on Tuesday, September 12th.

How Many Honeywell International Inc. (NYSE:HON)'s Analysts Are Bearish?
The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. Nine Chapters Capital Management Llc decreased Oracle Corporation (ORCL) stake by 76.72% reported in 2017Q2 SEC filing.

Dias: GM's plans to produce Equinox in Mexico 'war on Canada'
But he said Dias could be making the situation worse by being so firm on demands for long-term commitments from the automaker. GM has ample unused factory space in the US , but retooling one of those plants to make the Equinox could take a few years.